FDA keeps the faith in surrogate endpoints
The US regulator granted 14 accelerated approvals in 2019, fewer than in the previous two years, and the sector remains slow at conversions.
Biopharma’s big bet on cancer is laid bare
Drug developers have directed almost half of their dealmaking firepower at oncology projects over the past five years, with cardiovascular a distant second.
Cash-rich biotechs turn down the licensing deal volume
Last year saw a dip in licensing deals across biopharma, though up-front payments held up and in some areas jumped considerably.
The cost to Astrazeneca of building Brilinta
Thales, the final Brilinta outcome trial in Astrazeneca’s huge Parthenon programme, has hit – but the UK group’s vast investment in its blood thinner has yet to pay off.
Rare diseases top another strong year for novel drug approvals
A clutch of swift FDA decisions boosted average US drug approval times in 2019, helping biopharma to deliver another bumper crop of new medicines.
Sanofi's geriatric pipeline fails to freshen up
A look at the freshness of pharma's pipelines shows that Sanofi's new chief executive has his work cut out, while Lilly and Astrazeneca come up smelling of…
Poor fourth quarter mars strong year for medtech floats
The device sector enjoyed a mid-year IPO bonanza, but after getting away the class of 2019 had a torrid time.
Another blockbuster year looms for approvals
Biogen’s Alzheimer’s candidate and Fibrogen’s new anaemia pill top the list of the biggest commercial hopes that could reach the market in 2020.
A quiet six months for device approvals
The second half of 2019 saw half as many innovative medical devices approved as the first.
